GI biome

GI biome is a South Korean biotechnology company that develops microbiome-based combination therapies aimed at treating chronic conditions such as cancer, metabolic disorders, and autoimmune and inflammatory diseases. The company's core technology, μ+ Herbal Therapy, focuses on creating new treatments by leveraging the interaction between the gut microbiome and the immune system.

The company is led by CEO Bo-Gie Yang. GI biome operates several research facilities, including a Center for Preclinical Studies, a Central Lab, and a Center for Microbiome Informatics, to support its research and development pipeline. It collaborates with various global and local partners and research institutes to advance the development of its microbiome combination therapeutics. Through a partnership with Severance Hospital, GI biome is involved in a government-supported R&D project to develop protein drugs, antibody treatments, and synbiotic therapies for incurable diseases like terminal solid tumors and Crohn's disease.

The business model includes the development of its therapeutic pipeline and also the manufacturing of dietary supplements. The company aims to monetize its developments through pharmaceutical partnerships and the commercialization of its products. GI biome's vision is to lead the future of disease treatment by developing innovative therapies that improve the quality of life for patients with chronic illnesses.

Keywords: microbiome therapy, immuno-oncology, autoimmune disease treatment, inflammatory disease, metabolic disorders, synbiotics, gut health, biotechnology, pharmaceutical research, preclinical studies, clinical development, combination therapy, drug development, chronic disease treatment, protein drugs, antibody drugs, cell therapy, microbial therapeutics, gut-immune axis, life sciences